PMID- 35307714
OWN - NLM
STAT- MEDLINE
DCOM- 20220930
LR  - 20221004
IS  - 1473-5709 (Electronic)
IS  - 0959-8278 (Linking)
VI  - 31
IP  - 6
DP  - 2022 Nov 1
TI  - Type 2 diabetes mellitus and cancer of unknown primary risk: results from the 
      Netherlands Cohort Study.
PG  - 600-608
LID - 10.1097/CEJ.0000000000000749 [doi]
AB  - OBJECTIVE: Cancer of unknown primary (CUP) is a metastatic malignancy with an 
      unidentifiable primary tumour origin. Previous studies suggest that type 2 
      diabetes mellitus (T2DM) and CUP risk are associated. This study examines the 
      association in greater depth by investigating T2DM status, T2DM duration, T2DM 
      age at diagnosis, and medication that was being used in relation to CUP. METHODS: 
      Data were utilized from the Netherlands Cohort Study, a prospective cohort that 
      includes 120 852 participants aged 55-69 years at baseline in 1986. All 
      participants completed a self-administered questionnaire on cancer risk factors. 
      CUP cases were identified through record linkage with the Netherlands Cancer 
      Registry and Dutch Pathology Registry. After 20.3 years of follow-up, 963 
      incident CUP cases and 4288 subcohort members were available for case-cohort 
      analyses. Proportional hazards models were employed to estimate 
      multivariable-adjusted hazard ratios (HRs). RESULTS: Overall, we observed a 
      nonsignificant positive association between T2DM status and CUP risk [HR, 1.35; 
      95% confidence interval (CI), 0.92-1.99], which increased in women after 
      stratification for sex (HR, 1.55; 95% CI, 0.90-2.64). For participants who were 
      aged less than 50 years at diagnosis of T2DM, a statistically significant 
      positive association was found in relation to CUP (HR, 2.42; 95% CI, 1.26-4.65), 
      compared with participants without T2DM. CONCLUSION: Our findings indicate that 
      there is a nonsignificant positive association between T2DM and CUP risk and that 
      the association became stronger in women in stratified analyses.
CI  - Copyright (c) 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Hermans, Karlijn E P E
AU  - Hermans KEPE
AD  - Department of Epidemiology, GROW School for Oncology and Developmental Biology, 
      Maastricht University, Maastricht.
FAU - Haque, Sharmi
AU  - Haque S
AD  - Department of Epidemiology, GROW School for Oncology and Developmental Biology, 
      Maastricht University, Maastricht.
FAU - van den Brandt, Piet A
AU  - van den Brandt PA
AD  - Department of Epidemiology, GROW School for Oncology and Developmental Biology, 
      Maastricht University, Maastricht.
FAU - Loef, Caroline
AU  - Loef C
AD  - Department of Research, Comprehensive Cancer Organization the Netherlands, 
      Utrecht.
FAU - Jansen, Rob L H
AU  - Jansen RLH
AD  - Department of Internal Medicine, Medical Oncology, Maastricht University Medical 
      Center, Maastricht, The Netherlands.
FAU - Schouten, Leo J
AU  - Schouten LJ
AD  - Department of Epidemiology, GROW School for Oncology and Developmental Biology, 
      Maastricht University, Maastricht.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220505
PL  - England
TA  - Eur J Cancer Prev
JT  - European journal of cancer prevention : the official journal of the European 
      Cancer Prevention Organisation (ECP)
JID - 9300837
SB  - IM
MH  - Cohort Studies
MH  - *Diabetes Mellitus, Type 2/diagnosis/epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - *Neoplasms, Unknown Primary/complications/diagnosis/epidemiology
MH  - Netherlands/epidemiology
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
EDAT- 2022/03/22 06:00
MHDA- 2022/10/01 06:00
CRDT- 2022/03/21 05:44
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/10/01 06:00 [medline]
PHST- 2022/03/21 05:44 [entrez]
AID - 00008469-202211000-00014 [pii]
AID - 10.1097/CEJ.0000000000000749 [doi]
PST - ppublish
SO  - Eur J Cancer Prev. 2022 Nov 1;31(6):600-608. doi: 10.1097/CEJ.0000000000000749. 
      Epub 2022 May 5.